In this phase 2, single-arm, nonrandomized clinical trial that included 28 adults with Ph-positive ALL, the complete molecular remission rate after CD19 CAR T-cell therapy was 85%. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.